Last reviewed · How we verify
NCT06614699
Predictive Effect of Abdominal Fat and Muscle Area Calculated Based on Abdominal CT on Colorectal Cancer Patients
trial testing abdominal fat and muscle area in Colorectal Cancer in 8,000 participants. Participants enrolled and being followed up; not accepting new ones.
1 January 2024
Quick facts
| Lead sponsor | First Affiliated Hospital of Chongqing Medical University |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 8,000 |
| Start date | 1 January 2012 |
| Primary completion | 1 January 2024 |
| Estimated completion | 1 June 2025 |
| Sites | 3 locations across China |
Drugs / interventions tested
- abdominal fat and muscle area
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Sarcopenia — all drugs for Sarcopenia →
- Obesity and Overweight — all drugs for Obesity and Overweight →
Sponsor
First Affiliated Hospital of Chongqing Medical University
Who can join
18 and older, any sex, with Colorectal Cancer or Sarcopenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to create a clinical prediction model. Abdominal fat and muscle area also play an important role in the prediction of surgical outcomes in colorectal cancer. Studies have shown that excess visceral fat and low skeletal muscle mass (sarcopenia) are associated with poorer postoperative outcomes, including a higher risk of postoperative complications and lower survival. Preoperative imaging techniques such as CT, MRI and ultrasound that provide accurate measurements to assess abdominal fat and muscle area can help surgeons develop individualized surgical and rehabilitation plans, improve surgical success, reduce complications and improve long-term patient prognosis. In this study, the investigators expected to construct a prediction model of abdominal fat and muscle area on the short- and long-term outcomes of colorectal cancer patients by calculating the abdominal fat and muscle area in different levels of abdominal CT images, in order to further adjust and guide the treatment plan.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06614699
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other First Affiliated Hospital of Chongqing Medical University trials
Trials by the same sponsor.
- NCT07369713 — Efficacy and Safety of Accelerated Intermittent Theta-burst Stimulation (a-iTBS) in Adolescents With Depressive Disorder · NA · not yet recruiting
- NCT07499323 — Talquetamab in Patients With Refractory Generalized Myasthenia Gravis · NA · not yet recruiting
- NCT07409870 — An Integrated Multi-omics Study on the Molecular Mechanisms of Ureteral Stricture · not yet recruiting
- NCT07324473 — Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired R · Phase 2 · not yet recruiting
- NCT07203144 — Selenium Supplementation for Improving Depression in Children and Adolescents: Efficacy and Mechanistic Study · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06614699 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Chongqing Medical University
- Last refreshed: 27 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06614699.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing